Department of Pediatrics, Faculty of Medicine, Balikesir University, Balikesir 10145, Türkiye.
Department of Radiology, Faculty of Medicine, Balikesir University, Balikesir 10145, Türkiye.
Medicina (Kaunas). 2024 Aug 20;60(8):1355. doi: 10.3390/medicina60081355.
: This study was performed for the purpose of assessing whether antiepileptic levetiracetam treatment produces a change in brain volumes in children with epilepsy. To that end, we compared the volumes of the basal ganglia (caudate nucleus, putamen, globus, hip-pocampus, and thalamus) at magnetic resonance imaging (MRI) before and after treatment (months 18-24) in pediatric epilepsy patients using levetiracetam. : This retrospective study involved a volumetric comparison of patients presenting to the Balikesir University Medical Faculty pediatric neurology clinic between 01.08.2019 and 01.11.2023 and diagnosed with epilepsy, and who underwent cranial MRI before and 18-24 months after treatment at the radiology department. The demographic and clinical characteristics (age, sex, family history of epilepsy, type of epilepsy, and EEG features (normal, abnormal, epileptiform)) of the patients included in the study were recorded. The comparison of basal ganglia volumes at cranial MRI before and at months 18-24 of treatment revealed significant differences in the left caudate nucleus, right putamen, left putamen, left globus pallidus, right thalamus, left thalamus, and right hippocampal regions. In conclusion, differing findings are encountered at cranial imaging in patients with epilepsy, depending on the seizure frequency, activity, and the type of antiepileptic drugs used. This study compared basal ganglia volumes on cranial MRIs taken before and 18-24 months after treatment in pediatric epilepsy patients using levetiracetam. A significant increase was observed in the volumes of basal ganglia (caudate nucleus, putamen, globus pallidus, hippocampus, and thalamus) on the MRIs of pediatric epilepsy patients using levetiracetam.
这项研究旨在评估抗癫痫药物左乙拉西坦治疗是否会导致癫痫儿童的脑体积发生变化。为此,我们比较了使用左乙拉西坦治疗的儿科癫痫患者在治疗前(18-24 个月)和治疗后(18-24 个月)磁共振成像(MRI)的基底节(尾状核、壳核、苍白球、海马体和丘脑)体积。这项回顾性研究涉及对 2019 年 8 月 1 日至 2023 年 11 月 1 日期间在巴利克西尔大学医学系儿科神经科诊所就诊的癫痫患者进行容积比较,这些患者在放射科接受了治疗前和治疗后 18-24 个月的头颅 MRI 检查。记录了患者的人口统计学和临床特征(年龄、性别、癫痫家族史、癫痫类型和脑电图特征(正常、异常、癫痫样))。治疗前和治疗后 18-24 个月的头颅 MRI 显示左尾状核、右壳核、左壳核、左苍白球、右丘脑、左丘脑和右海马体区域的基底节体积存在显著差异。总之,根据癫痫发作频率、活动和使用的抗癫痫药物类型,癫痫患者的头颅影像学表现存在不同的发现。本研究比较了使用左乙拉西坦治疗的儿科癫痫患者治疗前和治疗后 18-24 个月的头颅 MRI 基底节体积。使用左乙拉西坦治疗的儿科癫痫患者的基底节(尾状核、壳核、苍白球、海马体和丘脑)体积在 MRI 上显著增加。